BERLIN – German health technology company Siemens Healthineers said Thursday its revenues in the fiscal year 2021 that ended on Sept 30 rose by 19.3 percent year-on-year to reach the record figure of almost 18 billion euros ($20.7 billion) on a comparable basis.
The contribution to sales from rapid COVID-19 antigen tests was around 1.1 billion euros. Without these, there would only be comparable total revenue growth of 11.8 percent, according to the company.
After 1.4 billion euros last year, net income of Siemens Healthineers was now as high as 1.7 billion euros, it said.
Siemens Healthineers “successfully ended the record year 2021 with a strong quarter,” said CEO Bernd Montag, speaking of an “agile and prudent response” to the COVID-19 pandemic.
The company”s full-year revenues in China jumped 24 percent, reaching 2.4 billion euros, while revenues in the United States increased by 11 percent to 5.5 billion euros. Figures for the home market of Germany skyrocketed 100 percent and reached 1.7 billion euros.
In fiscal 2021, the figures for the US cancer therapy specialist Varian, which was acquired in April, were included for the first time. The subsidiary’s total adjusted revenues in the fourth quarter stood at 709 million euros, according to Siemens Healthineers.
For fiscal year 2022, the company expects revenue growth of up to two percent compared to 2021.
The many different trade and aid policies being pursued by China globally have been heavily criticised but can developing countries become more independent or will China’s policy reform?